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Frederic Baron, MD, PhD,f Carine Wouters, MD, PhD,c,d and Adrian Liston, PhDa,b Leuven and Liege, BelgiumBackground: Hemophagocytic lymphohistiocytosis (HLH) is a
severe inflammatory condition driven by excessive CD81 T-cell
activation. HLH occurs as both acquired and familial
hemophagocytic lymphohistiocytosis (FHL) forms. In both
conditions, a sterile or infectious trigger is required for disease
initiation, which then becomes self-sustaining and life-
threatening. Recent studies have attributed the key distal event
to excessive IFN-g production; however, the proximal events
driving immune dysregulation have remained undefined.
Objective: We sought to investigate the role of regulatory T
(Treg) cells in the pathophysiology of experimental FHL.
Methods: Because mutation in perforin is a common cause of
FHL, we used an experimental FHL mouse model in which
disease in perforin-deficient mice is triggered by lymphocytic
choriomeningitis virus (LCMV). We assessed Treg and CD81
T-cell homeostasis and activation during the changing systemic
conditions in the mice. In addition, human blood samples were
collected and analyzed during the HLH episode.
Results: We found no primary Treg cell defects in perforin-
deficient mice. However, Treg cell numbers collapsed after
LCMV inoculation. The collapse of Treg cell numbers in
LCMV-triggered perforin-deficient, but not wild-type, mice was
accompanied by the combination of lower IL-2 secretion by
conventional CD41 T cells, increased IL-2 consumption by
activated CD81 T cells, and secretion of competitive soluble
CD25. Moreover low Treg cell numbers were observed in
untreated patients experiencing HLH flares.
Conclusion: These results demonstrate that excessive CD81
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http://dx.doi.org/10.1016/j.jaci.2015.12.1314from Treg cell maintenance and toward feed-forward
inflammation. These results also provide a potential mechanistic
pathway for the progression of infectious inflammation to
persistent inflammation in patients with HLH. (J Allergy Clin
Immunol 2016;nnn:nnn-nnn.)
Key words: Regulatory T cells, familial hemophagocytic lymphohis-
tiocytosis, IL-2, immune homeostasis, perforin, lymphocytic chorio-
meningitis virus
Hemophagocytic lymphohistiocytosis (HLH) is a severe in-
flammatory immune syndrome characterized by prolonged fever
with hepatosplenomegaly, cytopenia, hepatitis, and neurologic
manifestations.1,2 The principal immunologic features of this
syndrome are uncontrolled expansion of CD81 cytotoxic
T cells, activation of antigen-presenting cells/macrophages
(histiocytes), natural killer cell dysfunction, and florid cytokine
storm, including high amounts of IFN-g and TNF-a. Clinical
manifestations are a consequence of hypercytokinemia and
infiltration by activated lymphocytes and histiocytes of the bone
marrow, spleen, liver, and central nervous system.1,2
Familial hemophagocytic lymphohistiocytosis (FHL) is caused
by genetic deficiency in the cytotoxic pathways of T and natural
killer cells, with mutations in the genes encoding perforin (Prf1)
or the perforin secretion components Munc13-4, Munc18-2, or
Syntaxin 11 accounting for most cases.2 A secondary form of
acquired HLH can also arise after a broad variety of initiators,
including infections, malignancies, or autoimmune diseases,
with a specific condition called macrophage activation syndrome
(MAS) mainly diagnosed in patients with systemic juvenile
idiopathic arthritis.1,2
Despite progress in our understanding of HLH pathogenesis,
treatment of HLH has remained unsatisfactory. In addition to
treating the trigger event, current treatments for HLH are based on
highly immunosuppressive drugs and chemotherapy, whereas
allogeneic hematopoietic stem cell transplantation can be
considered in patients with FHL and severe forms of HLH.3
Preclinical models for studying FHL have been developed
using lymphocytic choriomeningitis virus (LCMV)–triggering
inflammation in perforin-deficient mice.4,5 These murine models
recapitulate the key components of human disease, including
life-threatening inflammation, cytopenia, cytokine storm, and
immune cell infiltration in different organs, including the liver
and central nervous system. Specifically, these studies helped to
uncover the pathophysiology of FHL, demonstrating that both
CD81 T cells and IFN-g are the principal terminal effectors of
the disease. In addition, sustained antigen presentation has been
reported to be essential to trigger CD81 activation,6 and most
patients with FHL have a history of viral infections acting as1
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perplexing aspects of the clinical presentation of HLH, namely
that some patients are given a diagnosis after the (presumably)
viral trigger has been cleared, with self-perpetuating sterile
inflammation developing. In addition, in utero FHL diseases
have been described,7,8 again indicating the capacity for the
disease to be noncontingent on persistent infection. This
observation indicates that we are currently still missing a key
step in the pathogenesis of HLH, namely how excessive IFN-g
production and CD81 T-cell activation during a viral infection
can continue and progress into a persistent hyperinflammatory
state independent of viral burden. This process suggests that
excessive CD81 T-cell activation might require additional
proximal events to develop into the relentless inflammatory state
of HLH.
One potential player in the pathogenic process of HLH might
be regulatory T (Treg) cells.9 Treg cells have a unique suppressive
function in the immune system, a function imparted by the
transcription factor forkhead box protein P3 (Foxp3). Mutations
in FOXP3 cause a fatal autoimmune and inflammatory disorder
in both human subjects (immune dysregulation, polyendocrinop-
athy, enteropathy, X-linked [IPEX] syndrome) and mice (Scurfy
mice). In addition, defects in Treg cell homeostasis promote
autoimmunity and inflammation in patients with multiple other
disorders,10,11 demonstrating the vital role of Treg cells in
preventing systemic inflammation. Here, we sought to determine
whether Treg cells were involved in the malfunction of immune
suppression that allows defective antiviral immunity to progress
to fatal systemic inflammation in patients with FHL. Using
LCMV-driven inflammation in perforin-deficient mice, we
demonstrate that excessive activation of CD81 T cells during
FHL creates an IL-2–limiting environment and reverses the
IL-2 consumption hierarchy. These processes drive a collapse
of the Treg cell population in both mice and patients and provide
potential mechanistic explanation for the progression of infec-
tious inflammation into the persistent systemic inflammation
characteristic of HLH.METHODS
Patients
Diagnostic datawere obtained from patients with FHL/MAS during routine
clinical care at UZ Leuven. Neonatal patients were excluded from analysis. Of
the 7 patients identified during active FHL/MAS, 3 had not received any
treatment related to an FHL/MAS episode at the time of the analysis, whereas
4 other patients had already started corticosteroids, cyclosporine treatment, orboth. Written informed consent was obtained from each patient. The Ethics
Committee of the University of Leuven and University Hospital approved the
consent form and the current research study.
Mice
Perforin-deficient (C57BL/6-Prf1tm1Sdz/J, Jackson Laboratory, Bar Harbor,
Me) and C57BL/6 controls (Charles River, Wilmington, Mass) were analyzed
at 8 to 12 weeks of age. Perforin-deficient mice were backcrossed to the
Cd127Cre/wtMcl1fl/wt background12,13 for use of the huCD4 reporter. Mice
were maintained in specific pathogen-free facilities at the University of
Leuven. All experiments were approved by the University of Leuven and
the University of Liege Animal Ethics Committee.
Virus and infection
LCMV-Armstrong was produced and titrated, as previously described.14
Mice were infected with 105 plaque-forming units of LCMV-Armstrong
intraperitoneally on day 0 and were monitored and analyzed at day 10 after
infection, unless otherwise specified. A subset of mice were administered
murine IL-2/anti–IL-2 immune complex (1.5 mg/15 mg per mouse,
JES6-1A12 clone; eBioscience, San Diego, Calif) intraperitoneally every
other day starting on day 0 with LCMV injection.Mouse blood analysis
Mouse blood samples were analyzed with the CELL-DYN 3700 (Abbott,
Abbott Park, Ill) to determine red cell and platelet counts, aswell as hematocrit
and hemoglobin contents.
Flow cytometry
Single-cell suspensions were prepared from mouse spleens and pooled
lymph nodes (cervical, inguinal, mesenteric, axillary, and brachial). For
intracellular cytokine staining, lymphocytes were plated at 53 105 cells/well
in 96-well tissue-culture plates in complete RPMI containing phorbol
12-myristate 13-acetate (50 ng/mL; Sigma-Aldrich, St Louis,Mo), ionomycin
(250 ng/mL, Sigma-Aldrich), and monensin (1:1500; BD Bioscience, San
Jose, Calif) for 4 hours at 378C. All cells were fixed with BD Cytofix (BD
Biosciences) or fixed and permeabilized with the eBioscience Foxp3 staining
kit (eBioscience). For phospho–signal transducer and activator of transcrip-
tion 5 (STAT5) staining, lymphocytes were plated at 5 3 106 cells/well in
96-well tissue-culture plates in complete RPMI containing murine IL-2
(100 ng/mL, eBioscience) and stimulated for 30 minutes before fixation
with IC Fixation Buffer (eBioscience) and methanol. Anti-murine antibodies
included anti-CD4 (RM4-5), anti-CD8a (53-6.7), anti-FoxP3 (FJK-16s),
anti-CD25 (PC61.5), anti–cytotoxic T lymphocyte–associated antigen 4
(CTLA4; UC10-4B9), anti-CD69 (H1.2F3), anti-CD103 (2E7), anti-CD44
(IM7), anti-CD62L (MEL-14), anti–IL-2 (JES6-5H4), anti–IFN-g
(XMG1.2), and anti–phospho-STAT5 (SRBCZX) from eBioscience and
anti-Ki67 (B56) from BD Biosciences. Anti-human CD4 staining was
performed with BV-421 (OKT4; BioLegend, San Diego, Calif). Human
peripheral blood was stained with anti-human antibodies, including
anti-CD4 (5K3), anti-CD25 (2A3), and anti-CD127 (hIL-7R-M21). Data
were collected on a BD FACSCanto II (BD Biosciences) and analyzed with
FlowJo software for Mac, version 9.6 (TreeStar, Ashland, Ore).CD81 in vitro stimulation
Purified CD81 T cells were isolated from spleens and lymph nodes of wild-
type and IFN-g–deficient mice (Jackson Laboratory) by using untouched
CD81 magnetic isolation (STEMCELL Technologies, Vancouver, British
Columbia, Canada). Cells were cultured in complete RPMI media and stimu-
lated with phorbol 12-myristate 13-acetate (25 ng/mL, Sigma-Aldrich) and
ionomycin (250 ng/mL, Sigma-Aldrich) or anti-CD3 (10 mg/mL, precoated
overnight at 48C; BD Biosciences) with or without additional IFN-g
(500 ng/mL, eBioscience) in addition to recombination-activating gene
2–deficient splenocytes. Supernatants and cells were harvested 48 hours later.
FIG 1. Treg cell collapse during LCMV-induced HLH. Wild-type mice and Prf12/2 mice were infected with
LCMV-Armstrong. A, Mouse weight. B, Hemogram value with RBCs, hemoglobin, and hematocrit (day
10). C, Platelet level (day 10). D-F, Percentage of CD41Foxp31 Treg cells in lymph nodes (LN; Fig 1, D)
and percentage (Fig 1, E) and numbers (Fig 1, F) in the spleen (day 10). Median and individual data points
are shown. Fig 1, A, Representative of 7 experiments. Fig 1, B-F, Results pooled from 2 to 7 experiments.
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Soluble CD25 (sCD25) titers in individual plasma samples and superna-
tants were determined by using a mouse IL-2Ra DuoSet ELISA (R&D
Systems, Minneapolis, Minn), according to the manufacturer’s protocol.Statistical analyses
Single comparisons were analyzed by using the nonparametric
Mann-Whitney U test. Spearman correlation was used for correlation tests.
All statistical analyses were carried out with GraphPad Prism (version 5;
GraphPad Software, La Jolla, Calif).RESULTS
Defective Treg cell homeostasis during HLH
To determine the proximal cause of uncontrolled inflammation
in patients with FHL, we investigated the properties of Treg cells,
one of the key regulators of immune activation. Perforin knockout
(Prf12/2) mice, with the same underlining genetic deficiency as
patients with FHL, were used to assess Treg cell status. To
investigate Treg cell homeostasis during inflammation in an
FHL murine model, wild-type and Prf12/2 mice were treated
with LCMV (Armstrong strain). After infection, wild-type mice
experienced a transient immune activation with splenomegaly,
whereas Prf12/2 mice had a terminal inflammatory disease that
recapitulated the key aspects of FHL, including wasting,
inflammatory anemia, and thrombocytopenia (Fig 1, A-C), as
previously reported.4,15 Disease was also associated with reducedsplenic monocyte and increased neutrophil counts (see Fig E1 in
this article’s Online Repository at www.jacionline.org). In the
absence of inflammation and at day 5 after infection, Prf12/2
mice had the same number of Treg cells as wild-type mice, as
defined by Foxp3-expressing cells within CD41 T cells,
indicating no primary defect in Treg cell homeostasis (Fig 1, D
and E). However, 10 days after infection, the Treg cell population
in wild-type mice infected with LCMV was reduced by
approximately 40%, whereas perforin-deficient mice experience
a collapse in Treg cell numbers, with an approximately 90%
reduction in the spleen and an approximately 40% reduction in
lymph nodes (Fig 1, D-F). These results indicate that although
Treg cells function normally in uninfected perforin-deficient
mice, FHL development is accompanied by a severe contraction
in the Treg cell compartment.
To determine the basis for reduced Treg cell numbers during
FHL, we phenotyped Treg cells fromwild-type and Prf12/2mice
after LCMV infection. Treg cells from wild-type mice showed
signs of activation during LCMV infection, with a transient
increase in the percentage of Treg cells expressing CD69
(Fig 2, A), whereas CTLA4 (Fig 2, B) and CD103 (Fig 2, C)
expression remains stable. Treg cells from Prf12/2mice infected
with LCMV, by contrast, showed greater levels of activation, with
a sustained upregulation of CD69 (Fig 2,A) and CTLA4 (Fig 2,B)
that is consistent with the activation of Treg cells by inflammatory
environments.16 Paradoxically, expression of Foxp3 and CD103
was reduced on Treg cells from Prf12/2 mice in comparison
FIG 2. Differential activation of Treg cells during FHL inflammation. Wild-type and Prf12/2 mice were
infected with LCMV-Armstrong and assessed for Treg cell activation profile in the lymph nodes.
A-C, Expression of CD69 (Fig 2, A), CTLA4 (Fig 2, B), and CD103 (Fig 2, C) on Treg cells. D, Representative
flow cytometric plot (left) and percentage (right) of Foxp3high cells on total Foxp31 Treg cells (day 10).
E, Intracellular Ki67 expression in Treg cells (day 10). WT, Wild-type. Median and individual data points
are shown. Results are pooled from 2 to 7 experiments.
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of Treg cells in the lymph nodes of Prf12/2 mice was dampened
(Fig 2, E). Similar results were observed in the spleen (see Fig E2
in this article’s Online Repository at www.jacionline.org).
Because it has previously been demonstrated that IL-2 is required
for optimal Foxp3 expression,17 CD103 upregulation,18 and Treg
cell proliferation,19 these results together suggest an impairment
of the Treg–IL-2 homeostatic network. Together, these data
demonstrate that an acquired peripheral Treg cell homeostasis
defect develops in LCMV-infected Prf12/2 mice, but not
wild-type mice, coincident with the hyperinflammatory state
of HLH.LCMV infection in perforin-deficient mice disrupts
IL-2 consumption
To determine the proximal cause of defective Treg cell
homeostasis in LCMV-infected perforin-deficient mice, we
further investigated the IL-2 homeostatic network during murine
HLH. Direct quantification of the low concentration of IL-2
present in mouse serum remains challenging. However, because
the main source of IL-2 provision to Treg cells is CD41 T cells,20
IL-2 production could be measured. By using intracellular
cytokine staining, IL-2 secretion was consistently lower in
CD41 T cells from infected Prf12/2 mice compared with
wild-type mice (Fig 3, A). Moreover, because of the hyperinflam-
matory status, total CD41 T-cell counts were significantly
decreased in both the spleens and lymph nodes of Prf12/2
compared with wild-type mice, exacerbating the defect in IL-2
production (Fig 3, B, and see Fig E3, A, in this article’s Online
Repository at www.jacionline.org). Absolute IL-2–producingCD41 T-cell numbers decreased to an even greater extent (data
not shown). By contrast, IL-2 production in CD81 T cells was
not modified by the loss of perforin (see Fig E4 in this article’s
Online Repository at www.jacionline.org). Indirect assessment
of IL-2 consumption by Treg cells is possible by studying expres-
sion of CD25 (IL-2 receptor a) on the cell surface, which is
closely correlated with IL-2 consumption levels because of a
STAT5-dependent positive feedback loop mechanism that
increases CD25 expression at the cell surface.21 Analysis of
mean fluorescence expression of CD25 on Treg cells in lymph
nodes after infection showed a significant reduction of CD25
expression in Prf12/2 mice compared with that seen in
wild-type mice, strongly supporting the hypothesis of a lack of
access to IL-2 for the Prf12/2 Treg cells (Fig 3, C). By contrast,
splenic Treg cells did not demonstrate reduced CD25 expression
(see Fig E3, B); however, Mcl1 expression downstream of IL-2
signaling in Treg cells was reduced in LCMV-infected Prf12/2
Treg cells (Fig 3, D), which is consistent with the role of IL-2
in maintaining the prosurvival Mcl1,19 providing a potential
mechanistic explanation for the observed death of Treg cells.Excessive CD81 T-cell activation leads to reversal of
IL-2 consumption hierarchy
IL-2 was discovered to be a potent T-cell growth factor,22 with
the immunoregulatory function of IL-2 generated by a
consumption hierarchy whereby Treg cells express higher levels
of CD25 than effector T cells. This hierarchy for consumption
not only allows IL-2 to function as a rheostat for Treg cell
numbers19,20 but is also a proposed mechanism for Treg cell
suppression of effector T cells.23 We investigated whether this
FIG 3. Limiting IL-2 availability in perforin-deficient mice during LCMV-triggered inflammation. Total CD41
T cells and IL-2 secretion were assessed in the lymph nodes of wild-type and Prf12/2 mice at day 10 after
LCMV infection. A, IL-2 secretion by CD41 T cells, with representative flow cytometric plot (left) and graph
(right). B, Percentage of CD41 cells within total lymphocytes. C, CD25 mean fluorescence intensity (MFI) in
the CD251 Treg cell population.N.S., Not significant.D, Expression of huCD4 reporter forMcl1 expression in
splenic Foxp31 Treg cells from CD127CreMcl1wt/flPrf1wt/wt and CD127CreMcl1wt/flPrf12/2mice (n5 3 mice per
group). Representative histogram (left) and geometric mean fluorescence intensity (MFI; right) are shown.
Median and individual data points are shown. Fig 3, A, Representative of 3 experiments. Fig 3, A-C, Results
pooled from 3 to 7 experiments.
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inflammatory environment of murine HLH. LCMV infection
results in a highly activated CD81 T-cell profile. In a wild-type
mouse the immune reaction peaks around days 7 to 8 after viral
exposure, whereas infection is controlled by day 10 with
clearance of all viral particles (data not shown). Indeed, we
observed that the majority of the CD81 T cells shifted from a
naive to an effector profile from day 5 to day 10 in
LCMV-infected wild-type mice (Fig 4, A and B, and see Fig
E5, A in this article’s Online Repository at www.jacionline.org).
In Prf12/2 mice the activation profile at day 5 remained similar
to that of wild-type mice; however, the activation to an effector
memory status was much more profound by day 10 (Fig 4, A
and B, and see Fig E5, A), which is consistent with poorer
viral clearance. This excessive CD81 T-cell activation in
LCMV-infected Prf12/2 mice was also demonstrated by the
increased expression of activation molecules, such as CD69
(Fig 4, C, and see Fig E5, B) and intracellular IFN-g (Fig 4, D).
More striking was the very high numbers of CD25-expressing
CD81 T cells in Prf12/2 mice on day 10, which in wild-type
mice shows only a low transient increase (Fig 4, E, and see
Fig E5, C).
CD81 T cells from Prf12/2 mice also showed much greater
CD25 expression on a per-cell basis. This 14-fold increase of
CD25 expression on activated CD81 T cells from Prf12/2mice, coupled with the approximately 2-fold decrease of CD25
on Treg cells, inverts the normal hierarchy for IL-2 affinity,
with activated CD81 T cells from Prf12/2 but not wild-type
mice having higher CD25 expression than Treg cells (Fig 4, F
and G, and see Fig E5, D). This resulting competitive advantage
for IL-2 capture resulted in greatly enhanced IL-2 signaling
capacity of activated CD81 T cells in Prf12/2 mice, with a
very high level of phospho-STAT5 activity in CD81 T cells
from LCMV-infected Prf12/2 mice compared with those from
wild-type infected mice (Fig 4, H and I, and see Fig E5, E). The
increase in CD25 expression on CD81 T cells is likely driven
by a combination of increased antigenic stimulation (higher
LCMV titers) and the autocrine effects of increased IFN-g
because in vitro modeling demonstrated that increased CD25
expression in CD81 T cells after T-cell receptor stimulation is
reduced in IFN-g–deficient CD81 T cells but can be restored
by the addition of exogenous IFN-g (Fig 5).
A high sCD25 level reflecting T-cell activation in the serum is
one of the diagnostic criteria in patients with FHL.1,2 This
prompted us to measure sCD25 levels in our model. Importantly,
we observed extremely high sCD25 levels in Prf12/2 mice sera
compared with wild-type mice on day 10 after infection (Fig 6,
A). This not only recapitulates a key component of FHL, but
because sCD25 might have the capacity to compete with CD25
for IL-2 binding,24 it adds an additional mechanism by which
FIG 4. Excessive CD81 T-cell activation inverts the IL-2 consumption hierarchy in perforin-deficient mice.
Wild-type and Prf12/2 mice were infected with LCMV-Armstrong and assessed at days 0, 5, and 10 for
CD81 T-cell activation in the lymph nodes. A, CD81 T-cell subpopulations were characterized as
CD81CD62L1CD442 naive cells, CD81CD62L1CD441 central memory T cells (TCM), and CD81CD62L2CD441
effector memory T cells (TEM) by means of flow cytometry. B, Percentage of CD81 naive, TCM, and TEM
cells. C-E, Percentage of CD81 T cells expressing CD69 (Fig 4, C), intracellular IFN-g (on day 10; Fig 4, D),
and CD25 (left) and CD25 geometric mean fluorescence intensity on total CD81 T cells at day 10 (right;
Fig 4, E). F and G, Representative flow cytometry profiles of CD25 expression on CD81 T cells (gray) and
Treg cells (black) in wild-type and Prf12/2 mice on day 10 (Fig 4, F) and geometric mean fluorescence
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=FIG 5. Synergistic effectsof anti-CD3stimulationand IFN-gonCD25expressionbyCD81Tcells.Wild-typeand
Ifng2/2 CD81 T cells were stimulated in vitro and analyzed for CD25 expression by using flow cytometry. A,
Representative flow cytometry profiles of CD25 expression on CD81 T cells from wild-type and Ifng2/2mice.
B and C, Percentage of CD81 T cells expressing CD25 (Fig 5, B) and geometric mean fluorescence intensity
(MFI) on CD251CD81 T cells (Fig 5, C). APC, Antigen-presenting cells; PMA/Ion., phorbol 12-myristate 13-
acetate/ionomycin.Median and individual data points are shown. Results are representative of 3 experiments.
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infection. Because of the greatly increased level of CD25 expres-
sion on CD81T cells (Fig 4,F), we investigated CD81T cells as a
source for sCD25. Within infected mice, there was a significant
correlation between sCD25 levels and CD25 expression on the
surface of CD81 T cells (Fig 6, B, and see Fig E6 in this article’s
Online Repository at www.jacionline.org), and in vitro activated
CD81T cells shed sCD25 into the supernatant (Fig 6,C). Overall,
these data show that uncontrolled activation of CD81 T cells
during LCMV-triggered inflammation in Prf12/2 mice contrib-
utes to IL-2 deficiency through competitive IL-2 consumption
and sCD25 shedding.Diversion of the IL-2 negative feedback regulatory
network into an inflammatory feed-forward
network
The homeostatic IL-2 regulatory network allows in vivo expan-
sion of Treg cells through supplementation of IL-2 to supraphy-
siologic levels with IL-2/anti–IL-2 antibody complexes.25
Therefore we sought to determine whether we could prevent
lethal HLH in Prf12/2 mice by treating with IL-2 complexes
during LCMVinfection. Surprisingly, initial experiments resulted
in more rapid death of LCMV-infected Prf12/2 mice, with most
IL-2 complex–treated mice dying before day 10 (data not shown).
Analysis of LCMV-infected Prf12/2 mice with and without IL-2
complex treatment demonstrated that the additional IL-2
provision was able to restore the high level of CD25 expression
on the Treg cell surface (Fig 7, A), driving proliferation (Fig 7,
B) and increasing the size of the Treg cell compartment in some
mice (Fig 7, C). However, this significant improvement toward
immunosuppression was overridden by the counterproductiveintensity for CD25 expression on Foxp31 Treg cells and
t test. H and I, Representative flow cytometry histogram
mulated control (black line), wild-type (gray line), and P
LCMV infection (Fig 4, H) and percentage of positive p
Mean fluorescence intensity; WT, wild-type. Fig 4, A an
I, Representative of 1 to 2 experiments. Fig 4, B-E andeffect on CD81 T cells, which (as CD25high cells) also received
increased IL-2 signal, as reflected by a further increase in CD25
levels (Fig 7, D) and expansion (Fig 7, E). Critical for disease
progression, IL-2 complex treatment of Prf12/2 mice also
increased IFN-g production (Fig 7, F), the distal pathogenic event
in HLH. Similar results were observed in the spleen (see Fig E7 in
this article’s Online Repository at www.jacionline.org). In all,
these data demonstrate that the excessive activation of Prf12/2
CD81 T cells during LCMV infection results in both a reduction
of bioavailable IL-2 for Treg cells and also a diversion of IL-2
consumption from the anti-inflammatory Treg cell circuit to a
proinflammatory effector CD81 T-cell circuit. These results
suggest that altered IL-2 homeostasis contributes to the proximal
defects driving fatal inflammation during HLH and FHL.Patients with FHL/MAS experience low Treg cell
numbers during inflammatory flares
To provide proof-of-principle translation to the clinical setting,
we assessed patients with newly diagnosed FHL or MAS for Treg
cell numbers as part of clinical diagnostics (see Table E1 in this
article’s Online Repository at www.jacionline.org). Seven
patients with active FHL or MAS were assessed for Treg cell
numbers. Because of the rapid progression of disease, 4 patients
had already received treatment before blood sample analysis.
Of the untreated patients, all exhibited Treg cell frequencies in
the peripheral blood of less than the diagnostic standard range
(Fig 8). However, of the 4 patients who had already started
corticosteroids, cyclosporine treatment, or both, 3 had Treg cell
frequencies within the standard range, and the 1 patient with
lowTreg cell numbers after treatment died (Fig 8). Together, these
data demonstrate that the Treg cell count decrease observedCD251CD81 T cells, as assessed by using a paired
of phospho-STAT5 gated on CD81 T cells in unsti-
rf12/2mice (gray line with filled area) 10 days after
hospho-STAT5 within CD81 T cells (Fig 4, I). MFI,
d F, Representative of 7 experiments. Fig 4, H and
G, Results pooled from 2 to 7 experiments.
FIG 6. Increased secretion of sCD25 by activated CD81 T cells during FHL. A, sCD25 in serum from wild-type
(WT) and Prf12/2mice at day 10 after LCMV infection.B,Correlation betweenCD25-expressingCD81 T cells in
the lymphnodeswith respective sCD25 concentrations in serum(day10).C,Supernatant sCD25measurement
from in vitro–stimulated CD81 T cells. APC, Antigen-presenting cells; PMA/Ion., phorbol 12-myristate
13-acetate/ionomycin. Median and individual data points are shown. Data are pooled from 2 experiments.
FIG 7. IL-2 elicits a feed-forward inflammatory loop during LCMV-triggered disease. Wild-type (WT) and
Prf12/2 mice, with or without IL-2 complex treatment, were infected with LCMV-Armstrong. A-C, Lymph
node Treg cell counts were assessed (day 8) for CD25 geometric mean fluorescence intensity within
CD251 cells (Fig 7, A), Ki67 expression (Fig 7, B), and percentage within CD41 T cells (Fig 7, C). D-F, CD81
T cells were assessed for CD25 geometric mean fluorescence intensity (Fig 7, D), percentage within
lymphocytes (Fig 7, E), and IFN-g expression (Fig 7, F). MFI, Mean fluorescence intensity. Median and
individual data points are shown and pooled from 3 experiments.
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FIG 8. Low Treg cell numbers in patients with untreated FHL/MAS.
Peripheral blood from patients with an acute FHL/MAS episode were
assessed for the percentage of Treg cells (CD41CD251CD127low). Patients
were assessed before or after treatment. Fatality is indicated with an X.
Median and individual data points are shown. The healthy standard range
is represented in the gray shaded area.
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and suggest that immunosuppression restores Treg cell frequency.
We also note that the first patient with Treg cell–deficient IPEX
syndrome to undergo bone marrow transplantation had low donor
chimerism and later died of HLH.26 Together, these data indicate
that transient Treg cell deficiencywarrants further investigation as
a potential contributor to the proinflammatory environment
during clinical FHL/MAS. Such an effect might be driven by
the compounding effects of altered CD25 expression and reduced
IL-2 production and sCD25 levels, as we observe here in mice, or
in the patient context it might be primarily driven by the high
sCD25 level, which is already known to define FHL/MAS.DISCUSSION
In this report we describe the fate of Treg cells under the
debilitating condition of LCMV-induced FHL. We demonstrated
that after excessive activation of CD81 T cells, IL-2 production is
reduced and the consumption hierarchy is reversed, leading to
preferential consumption by inflammatory CD81 T cells to the
detriment of anti-inflammatory Treg cells.
Under physiologic conditions, Treg cells are important actors
in peripheral immune tolerance, creating a buffer against
spontaneous immune activation. Nevertheless, immune activation
is necessary during infection, and thus the Treg cell immunosup-
pression needs to be robust while also being surmountable. In a
recent report Srivasatva et al27 showed that wild-type mice have a
transient decrease in Treg cell numbers during LCMV infection,
an effect secondary to type I interferon signaling and one that
allows a proper immune reaction against the virus. Consistent
with this, Treg cells fromwild-type mice showed the same kinetic
profile in our study. Therefore a transient dip in Treg cell numbers
is a normal and even productive component of a strong
inflammatory response against viral stimuli. However, our data
indicate that in Prf12/2 mice the level of CD81 T-cell immune
activation crosses a critical threshold, at which point the CD81T cells become capable of diverting the normally anti-
inflammatory IL-2 feedback loop into a proinflammatory circuit,
driving the precipitous decrease in Treg cell numbers and
feed-forward inflammation. Several synergistic events appear to
participate in this process, with IL-2 production by CD41
T cells being suppressed28 (an effect that might be mediated
directly by IFN-g29) and release of sCD25 by CD81 T cells and
reversal of the CD25 expression hierarchy allowing preferential
consumption of IL-2 by CD81T cells at the expense of Treg cells.
Critically, this inverted hierarchy meant that IL-2 supplementa-
tion, which is normally protective in patients with Treg cell
deficiencies, drove excessive CD81 T-cell activation and led to
the premature death of Prf12/2 mice.
A critical component of the IL-2 feedback loops is the relation
between IL-2 availability and CD25 expression. In the
homeostatic state CD25 expression is essentially absent on
effector T cells, whereas it is a defining characteristic of Treg
cells, creating the consumption hierarchy.30,31 However, it is
noteworthy that inflammatory stimuli can upregulate CD25 on
CD81 T cells independent of the addition of IL-2,32 as shown
also by our in vitro experiment. Moreover, on the Treg cell side,
reduced IL-2 uptake will decrease Foxp3 expression, which in
turn will not sustain CD25high expression at the cell surface.21
Thus the normal transient events that occur during the early
response after viral infection in wild-type mice serve to reduce
the disparity in IL-2 consumptive capacity, creating an
immunologic context in which strongly reactive effector CD81
T cells can expand in a controlled manner. Once antigen
stimulation is removed, however, Treg cells regain disproportion-
ately high CD25 expression and thereby limit IL-2 availability for
other effector cells driving immune contraction.30,31 In the
context of HLH, however, the transient tempering of the Treg
cell IL-2 consumptive advantage is pushed even further by the
defective clearance of the viral trigger to allow highly activated
CD81 T cells to literally consume all available IL-2 to the
detriment of Treg cells. This rewiring of the IL-2 network results
in a destructive immune situation, which is acquired parallel to
the primary Treg cell deficiency of IPEX syndrome. Although
the primary genetic cause of the IL-2 network imbalance in
patients with FHL is a genetic defect in the perforin pathway
(increasing the chronicity of the CD81 T response), it is notable
that this rewiring could be driven by any immunologic event in
which CD81 T-cell activation exceeds a certain threshold, such
as occurs during Toxoplasma gondii infection in mice,29 or the
numerous nongenetic precipitating events in patients with HLH.
Regardless of the initial event, however, the acquired Treg cell
depletion will contribute to the severity of the inflammatory
environment and in particular to the extension of infection-
associated inflammation into persistent inflammation.
Overall, this study raises the possibility that HLH belongs in
the expanding set of Treg cell homeostasis disorders by
identifying the important role of the IL-2 network dysregulation
in patients with HLH. Furthermore, the underlying biology of this
dysregulation, with a reversal of the normal consumption
hierarchy, makes the disease refractory to IL-2 supplementation.
Indeed, 3 different clinical reports have shown positive clinical
outcomes in patients with HLH treated with anti-CD25
mAbs,33-35 whereas the efficacious cyclosporine treatment
directly suppresses IL-2 expression.36 Although it is counterintu-
itive that a disease of Treg cell homeostatic dysregulation would
positively respond to treatments that suppress IL-2 availability,
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performing the inverse (proinflammatory) function in patients
with HLH. These results suggest that the most efficacious
treatment route for HLH would be one in which CD81 T-cell
activation is inhibited while allowing Treg cell homeostasis to
recover, restoring the IL-2 homeostatic network to its
anti-inflammatory function, although further investigation of
the patient context would be required before any change to current
treatment strategies could be tested.
Key messages
d Treg cell numbers are severely decreased during murine
FHL.
d Excessively activated CD81 T cells during FHL outcom-
pete Treg cells for IL-2.
d Untreated patients with FHL/HLH experience Treg cell
reduction.
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FIG E1. Altered leukocyte compartment during FHL. Leukocyte subsets were analyzed in Prf12/2mice at day
10 after LCMV infection. A, Percentage of monocytes in spleen and blood. B, Percentage of neutrophils in
spleen. C, Percentage of natural killer (NK) cells in the spleen defined as NK1-11NKp461 cells. D, Absolute
NK cells in the spleen. E, Upregulation of CD107a in NK cells in the spleen. Median and individual data
points are shown. Fig E1, A and B, Results pooled from 7 experiments. Fig E1, C-E, Single experiment.
WT, Wild-type.
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FIG E2. Differential activation of Treg cells during FHL inflammation. Wild-type and Prf12/2 mice were
infected with LCMV-Armstrong and assessed at days 0, 5, and 10 for Treg cell activation profiles in the
spleen. A-C, Expression of CD69 (Fig E2, A), CTLA4 (Fig E2, B), and CD103 (Fig E2, C) on Treg cells from
wild-type and Prf12/2 mice. D, Percentage of Foxp3high cells on total Foxp31 Treg cells in wild-type and
Prf12/2 mice at day 10 after LCMV infection. E, Intracellular Ki67 expression in Treg cells in spleen on day
10 after LCMV infection. WT, Wild-type. Median and individual data points are shown. Results are pooled
from 2 to 7 experiments.
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FIG E3. Limiting IL-2 availability in perforin-deficient mice during LCMV-triggered inflammation. Total
CD41 T cells and IL-2 secretion were assessed in wild-type and Prf12/2mice at day 10 after LCMV infection.
A, Percentage of CD41 cells of total lymphocytes in the spleens of wild-type and Prf12/2 mice. B, CD25
expression determined by using geometric mean fluorescence intensity (MFI) in the splenic CD251 Treg
cell population. WT, Wild-type. Median and individual data points are shown. Results are pooled from 3
to 7 experiments.
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FIG E4. IL-2 production by CD81T cells is unchanged by perforin deficiency.
Total CD81 T cells and IL-2 secretion were assessed in wild-type (WT)
and Prf12/2 mice at day 10 after LCMV infection by using flow cytometry.
Percentage of IL-2 secreted by CD81 cells in the lymph nodes of wild-type
and Prf12/2mice. Results are pooled from 6 experiments.
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FIG E5. Excessive CD81 T-cell activation inverts the IL-2 consumption hierarchy in perforin-deficient mice.
Wild-type and Prf12/2mice were infected with LCMV-Armstrong and assessed at days 0, 5, and 10 for CD81
T-cell activation in the spleen. A, CD81 T-cell subpopulations were characterized as CD81CD62L1CD442
naive cells, CD81CD62L1CD441 central memory T cells (TCM), and CD81CD62L2CD442 effector memory
T cells (TEM) by using flow cytometry. The percentage of CD81 naive, TCM, and TEM cells in wild-type
mice and Prf12/2 mice after LCMV infection is shown. B-D, Percentage of CD81 T cells expressing CD69
(Fig E5, B), CD25 (Fig E5, C), and CD25 geometric mean fluorescence intensity (MFI; Fig E5, D) on total
CD81 T cells at day 10 after LCMV infection. E, Percentage of positive phospho-STAT5 within the CD81
T-cell population at days 0 and 10 after LCMV infection. Fig E5, A-D, Results pooled from 2 to 7
experiments. Fig E5, E, Representative of 1 to 2 experiments.
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FIG E6. Increased secretion of sCD25 by activated CD81 T cells during FHL.
Correlation between the percentage of splenic CD25-expressing CD81
T cells fromwild-type and Prf12/2mice with their respective sCD25 concen-
trations in serum is shown. The Spearman r value is 0.882. Median and
individual data points are shown. Data are pooled from 2 experiments.
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FIG E7. IL-2 elicits a feed-forward inflammatory loop during LCMV-triggered disease. Wild-type and Prf12/2
mice and Prf12/2 mice with or without IL-2 complex treatment were infected with LCMV-Armstrong. A-D,
Splenic Treg cell counts were assessed (day 8) for CD25 geometric mean fluorescence intensity within
CD251 cells (Fig E7, A), Ki67 expression (Fig E7, B), and percentage within CD41 T cells (Fig E7, C) and
absolute number (Fig E7, D). E-H, Splenic CD81 T cells were assessed for CD25 geometric mean
fluorescence intensity (Fig E7, E), percentage within lymphocytes (Fig E7, F), absolute number (Fig E7,
G), and IFN-g expression (Fig E7, H).MFI, Mean fluorescence intensity. Medians and individual data points
are shown pooled from 3 experiments.
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TABLE E1. Patients’ characteristics
Diagnosis Underlying disease Age Sex Prior treatment HLH treatment
1 MAS sJIA 11 mo Male — Corticosteroids
2 MAS sJIA 19 y Male Tocilizumab Corticosteroids
3 EBV-triggered FHL XLP (SAP deficiency) 10 mo Male — Corticosteroids and CyA
4 MAS sJIA 14 y Male — Corticosteroids*
5 EBV-induced MAS sJIA 21 y Male Tocilizumab —
6 MAS sJIA 13 y Female — —
7 FHL FHL (MUNC13-4 mutation) 15 mo Male — —
CyA, Cyclosporine; sJIA, systemic juvenile idiopathic arthritis; XLP, X-linked lymphoproliferative syndrome.
*Patient death during episode.
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